QQQ   437.88 (+0.60%)
AAPL   181.50 (+0.04%)
TSLA   204.65 (+1.29%)
NIO   5.58 (+2.76%)
T   16.99 (+0.18%)
CGC   3.40 (+1.19%)
AMC   4.62 (-7.41%)
PFE   27.11 (+0.26%)
QQQ   437.88 (+0.60%)
AAPL   181.50 (+0.04%)
TSLA   204.65 (+1.29%)
NIO   5.58 (+2.76%)
T   16.99 (+0.18%)
CGC   3.40 (+1.19%)
AMC   4.62 (-7.41%)
PFE   27.11 (+0.26%)
QQQ   437.88 (+0.60%)
AAPL   181.50 (+0.04%)
TSLA   204.65 (+1.29%)
NIO   5.58 (+2.76%)
T   16.99 (+0.18%)
CGC   3.40 (+1.19%)
AMC   4.62 (-7.41%)
PFE   27.11 (+0.26%)
QQQ   437.88 (+0.60%)
AAPL   181.50 (+0.04%)
TSLA   204.65 (+1.29%)
NIO   5.58 (+2.76%)
T   16.99 (+0.18%)
CGC   3.40 (+1.19%)
AMC   4.62 (-7.41%)
PFE   27.11 (+0.26%)

PTC Therapeutics (PTCT) Stock Price, News & Analysis

+0.05 (+0.18%)
(As of 08:36 AM ET)
Today's Range
50-Day Range
52-Week Range
130 shs
Average Volume
1.02 million shs
Market Capitalization
$2.13 billion
P/E Ratio
Dividend Yield
Price Target

PTC Therapeutics MarketRank™ Stock Analysis

Analyst Rating
1.86 Rating Score
21.4% Upside
$34.29 Price Target
Short Interest
13.76% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.98mentions of PTC Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$821,819 Sold Last Quarter
Proj. Earnings Growth
From ($5.83) to ($5.94) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.30 out of 5 stars

Medical Sector

342nd out of 958 stocks

Pharmaceutical Preparations Industry

164th out of 450 stocks

PTCT stock logo

About PTC Therapeutics Stock (NASDAQ:PTCT)

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTCT Stock Price History

PTCT Stock News Headlines

PTC Therapeutics Q4 2023 Earnings Preview
PTC Therapeutics Inc (PTCT)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
PTC Therapeutics (PTCT) to Release Quarterly Earnings on Thursday
PTCT Jun 2024 10.000 put
PTCT Mar 2024 19.000 put
Game-Changing Cancer Tech Nears FDA Completion
In the world of tech advancements, a new player could outshine even AI. It's a revolutionary technology with the aim of transforming cancer detection. Imagine the leap from basic reading glasses to cutting-edge VR; that's the scale of innovation we're talking about. FDA review is in its final stages and it could become the gold standard before we know it.
William Blair Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
DWAC, OCUL and APPF are among after hour movers
Stocks to Watch: Intel, PTC Therapeutics, KLA
RBC Capital Keeps Their Hold Rating on PTC Therapeutics (PTCT)
See More Headlines
Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
14 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$698.80 million
Book Value
($4.76) per share


Free Float
Market Cap
$2.13 billion
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

PTCT Stock Analysis - Frequently Asked Questions

Should I buy or sell PTC Therapeutics stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 5 sell ratings, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" PTCT shares.
View PTCT analyst ratings
or view top-rated stocks.

What is PTC Therapeutics' stock price target for 2024?

14 analysts have issued 12 month target prices for PTC Therapeutics' shares. Their PTCT share price targets range from $17.00 to $55.00. On average, they predict the company's stock price to reach $34.29 in the next year. This suggests a possible upside of 21.4% from the stock's current price.
View analysts price targets for PTCT
or view top-rated stocks among Wall Street analysts.

How have PTCT shares performed in 2024?

PTC Therapeutics' stock was trading at $27.56 at the start of the year. Since then, PTCT shares have increased by 2.5% and is now trading at $28.25.
View the best growth stocks for 2024 here

When is PTC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 29th 2024.
View our PTCT earnings forecast

How can I listen to PTC Therapeutics' earnings call?

PTC Therapeutics will be holding an earnings conference call on Thursday, February 29th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) issued its earnings results on Thursday, October, 26th. The biopharmaceutical company reported ($1.76) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by $0.91. The biopharmaceutical company earned $196.60 million during the quarter, compared to the consensus estimate of $210.23 million. PTC Therapeutics's revenue for the quarter was down 9.4% on a year-over-year basis. During the same period in the prior year, the company earned ($1.53) earnings per share.

What guidance has PTC Therapeutics issued on next quarter's earnings?

PTC Therapeutics updated its FY 2024 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $600.0 million-$850.0 million, compared to the consensus revenue estimate of $652.9 million.

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.66%), RTW Investments LP (9.84%), Armistice Capital LLC (9.10%), Price T Rowe Associates Inc. MD (1.32%), Price T Rowe Associates Inc. MD (1.32%) and Voloridge Investment Management LLC (1.09%). Insiders that own company stock include Alethia Young, Allan Steven Jacobson, Christine Marie Utter, David P Southwell, Dawn Svoronos, Emily Luisa Hill, Emma Reeve, Eric Pauwels, Mark Elliott Boulding, Matthew B Klein, Michael Schmertzler, Neil Gregory Almstead, Pierre Gravier, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends

How do I buy shares of PTC Therapeutics?

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PTCT) was last updated on 2/29/2024 by MarketBeat.com Staff